Clinical Trial Update: Low-dose Baricitinib Plus High-dose Dexamethasone for Patients With Newly Diagnosed Immune Thrombocytopenia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating low-dose baricitinib combined with high-dose dexamethasone for newly diagnosed immune thrombocytopenia. The status is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Baricitinib (baricitinib)
• DEXAMETHASONE (Dexamethasone)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Immune Thrombocytopenia | Phase 2 | Status: UNKNOWN